Directness and quality of evidence of bevacizumab combined with chemotherapy for platinum-resistant, recurrent ovarian cancer in the AURELIA trial:

G.L. Pappagallo; M. Rizzo

Directness and quality of evidence of bevacizumab combined with chemotherapy for platinum-resistant, recurrent ovarian cancer in the AURELIA trial

Authors

G.L. Pappagallo Clinical Trial Office, Department of Medical Oncology and Hemato-Oncology, Azienda ULSS 13, Mirano (VE), Italy.
M. Rizzo Medical Oncology Unit, A.Cardarelli Hospital, Naples, Italy.

Abstract

No abstract available

Downloads

Published

2014-10-15

How to Cite

Pappagallo G, Rizzo M. Directness and quality of evidence of bevacizumab combined with chemotherapy for platinum-resistant, recurrent ovarian cancer in the AURELIA trial: . CBN [Internet]. 2014 Oct. 15 [cited 2024 Nov. 23];2(2):39-41. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/274

Download Citation

Issue

Vol. 2 No. 2 (2014): October 2014

Section

Methodological corner

License

Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.